DS-1205c

DRUG2 trials

Sponsors

Daiichi Sankyo, Daiichi Sankyo Co., Ltd.

Conditions

Non Small Cell Lung CancerNon-small Cell Lung Cancer (NSCLC)

Phase 1

DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

TerminatedNCT03255083

Daiichi SankyoNon-small Cell Lung Cancer (NSCLC)

Start: 2019-04-10End: 2020-09-04Updated: 2022-01-19

DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

TerminatedNCT03599518

Daiichi Sankyo Co., Ltd.Non Small Cell Lung Cancer

Start: 2018-09-21End: 2020-06-29Updated: 2023-02-08

Related Papers

Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study.

2023-03-094 citations

Phase 1 study of DS‐1205c combined with gefitinib for EGFR mutation‐positive non‐small cell lung cancer

Cancer Medicine2023-01-098 citations

Phase I study of the AXL inhibitor DS-1205c in combination with osimertinib in subjects with metastatic or unresectable EGFR-mutant NSCLC

Annals of Oncology2018-10-011 citations